Compare Recursion Pharmaceuticals Inc (RXRX) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Sprott Uranium Miners ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.81B), while Sprott Uranium Miners ETF trades at $55.97. The key difference: Sprott Uranium Miners ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | URNM | |
|---|---|---|
Market Cap | $1.81B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $6.79 | $83.99 |
52-Week Low | $2.84 | $44.14 |
Enterprise Value | $1.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
URNM trades at $54.53, up 2.77% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF, focused on uranium miners, benefits from growing nuclear energy demand driven by AI power needs and government support, as highlighted in recent news. However, key financial ratios like P/E and P/S are unavailable, limiting fundamental clarity.
The outlook for URNM is positive due to structural tailwinds in nuclear energy, but risks include high volatility from commodity prices and concentrated miner exposure. Investors should weigh the bullish technical setup against the lack of transparent valuation metrics and potential sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
